Ranolazine was developed to protect the heart from transient ischemia, as may occur during angina and infarct. It has diverse effects at the cellular level, inhibiting late sodium and potassium currents and blocking ligand binding to α1, β1, and β2 adrenergic receptors.
|Chemical name||N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride|
|Solubility||Soluble up to 20mg/ml in DMSO and DMF|
|Regulatory statement||Product for research use only. Not intended for diagnostic or therapeutic use.|